Is LCTX (LCTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.6% / 30% | 11.2% / 30% | 0.1% / 30% | 18.05% / 5% | ✗ NOT HALAL |
| DJIM | 0.6% / 33% | 11.2% / 33% | 0.1% / 33% | 18.05% / 5% | ✗ NOT HALAL |
| MSCI | 2.2% / 33% | 42.2% / 33% | 0.6% / 33% | 18.05% / 5% | ✗ NOT HALAL |
| S&P | 0.6% / 33% | 11.2% / 33% | 0.1% / 33% | 18.05% / 5% | ✗ NOT HALAL |
| FTSE | 2.2% / 33% | 42.2% / 33% | 0.6% / 50% | 18.05% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -22.8% | |
| Operating Margin | -99.1% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -105.3% | |
| Return on Assets (ROA) | -12.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$23M |
| Free Cash Flow | -$24M |
| Total Debt | $3M |
| Debt-to-Equity | 5.6 |
| Current Ratio | 5.2 |
| Total Assets | $113M |
Price & Trading
| Last Close | $1.53 |
| 50-Day MA | $1.69 |
| 200-Day MA | $1.49 |
| Avg Volume | 1.1M |
| Beta | 1.8 |
|
52-Week Range
$0.37
| |
About LCTX (LCTX)
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is LCTX (LCTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), LCTX is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is LCTX's debt ratio?
LCTX's debt ratio is 0.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.2%.
What are LCTX's key financial metrics?
LCTX has a market capitalization of $371M, and revenue of $9M. Return on equity stands at -105.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.